MAPT and Alzheimer disease: Secondary outcomes included the classification of brain tau aggregates as determined by tau PET imaging, which has also been used by some trials in the selection of patients suitable for anti-amyloid immunotherapy7,38, and agreement with a clinical AD diagnosis.